ERBB2 and bone metastasis: No significant differences were observed in the rates of bone metastasis among patients with different ages (P = 0.467), menopausal status (P = 0.511), hormone receptors status (P = 0.517), Her2 status (P = 0.723) and molecular subtypes (P = 0.691).